---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023727"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:00:56.554244+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive

## Summary
- Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.
- Cash and equivalents $4.8M as of June 30, 2025, down from $9.9M at Dec 31, 2024; working capital $4.9M.
- Favorable CDI-988 Phase 1 safety/tolerability data for all doses including 1200 mg; Phase 1b norovirus challenge study planned in 2025.
- CC-42344 Phase 2a challenge study extended due to low influenza infection rates; compound active against H5N1 avian strain.
- R&D expenses $1.1M in Q2 2025 vs $4.3M in Q2 2024; G&A $1.0M vs $1.1M.

## SEC filing metadata
- accession: 0001641172-25-023727
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/0001641172-25-023727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023727
- JSON: https://secwatch.observer/filing/0001641172-25-023727.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.